Abstract
Background: Recent reports of the remarkable therapeutic efficacy of 225Ac-labeled PSMA- 617 for therapy of metastatic castration-resistant prostate cancer have underlined the clinical potential of targeted alpha therapy.
Objective and Conclusion: This review describes methods for the production of 225Ac and its daughter nuclide 213Bi and summarizes the current clinical experience with both alpha emitters with particular focus on recent studies of targeted alpha therapy of bladder cancer, brain tumors, neuroendocrine tumors and prostate cancer.
Keywords: Targeted alpha therapy, alpha emitter, actinium-225, bismuth-213, nuclide production, clinical application.
Current Radiopharmaceuticals
Title:An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth
Volume: 11 Issue: 3
Author(s): Alfred Morgenstern*, Christos Apostolidis, Clemens Kratochwil, Mike Sathekge, Leszek Krolicki and Frank Bruchertseifer
Affiliation:
- European Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, Karlsruhe,Germany
Keywords: Targeted alpha therapy, alpha emitter, actinium-225, bismuth-213, nuclide production, clinical application.
Abstract: Background: Recent reports of the remarkable therapeutic efficacy of 225Ac-labeled PSMA- 617 for therapy of metastatic castration-resistant prostate cancer have underlined the clinical potential of targeted alpha therapy.
Objective and Conclusion: This review describes methods for the production of 225Ac and its daughter nuclide 213Bi and summarizes the current clinical experience with both alpha emitters with particular focus on recent studies of targeted alpha therapy of bladder cancer, brain tumors, neuroendocrine tumors and prostate cancer.
Export Options
About this article
Cite this article as:
Morgenstern Alfred*, Apostolidis Christos, Kratochwil Clemens, Sathekge Mike, Krolicki Leszek and Bruchertseifer Frank, An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth, Current Radiopharmaceuticals 2018; 11 (3) . https://dx.doi.org/10.2174/1874471011666180502104524
DOI https://dx.doi.org/10.2174/1874471011666180502104524 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
[General Articles] Intracellular Thiol Concentration Modulating Inflammatory Response: Influence on the Regulation of Cell Functions Through Cysteine Prodrug Approach
Current Medicinal Chemistry Current Pharmacological Treatment for Male LUTS due to BPH: Dutasteride or Finasteride?
Current Drug Targets Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical Approaches
Current Medicinal Chemistry Targeting mTOR Signaling Pathway in Ovarian Cancer
Current Medicinal Chemistry Chondroitin Sulfate and Sulfur Containing Chondroprotective Agents: Is there a Basis for their Pharmacological Action?
Current Rheumatology Reviews Hitting the Golden TORget: Curcumin’s Effects on mTOR Signaling
Anti-Cancer Agents in Medicinal Chemistry Gene Therapy of Cancer with Interleukin-12
Current Pharmaceutical Design Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications
Current Pharmaceutical Design Mechanisms of Allostery and Membrane Attachment in Ras GTPases: Implications for Anti-Cancer Drug Discovery
Current Medicinal Chemistry Emerging Therapies Targeting Tumor Vasculature in Multiple Myeloma and other Hematologic and Solid Malignancies
Current Cancer Drug Targets Inflammatory and Non-Inflammatory Roles for Toll-Like Receptors in Gastrointestinal Cancer
Current Pharmaceutical Design DLEU2: A Meaningful Long Noncoding RNA in Oncogenesis
Current Pharmaceutical Design Vaccination Against Angiogenesis-Associated Antigens: A Novel Cancer Immunotherapy Strategy
Current Molecular Medicine Improved Pharmacokinetic Profile and Anti-Inflammatory Property of a Novel Curcumin Derivative, A50
Letters in Drug Design & Discovery Modulation of the Ceramide Level, A Novel Therapeutic Concept
Current Drug Targets Current Scenario of 1,4-Diazepines as Potent Biomolecules-A Mini Review
Mini-Reviews in Medicinal Chemistry Prediction by Pharmacogenetics of Safety and Efficacy of Non-Steroidal Anti- Inflammatory Drugs: A Review
Current Drug Metabolism Metabolite Identification in NMR-based Metabolomics
Current Metabolomics Doxorubicin Sensitizes the Non-Small Cell Lung Cancer Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated (TRAIL) Apoptosis In Vitro but not In Vivo
Letters in Drug Design & Discovery Chemotherapy for Prostate Cancer
Current Pharmaceutical Design